Microsoft word - parent survey report 31.7.09.doc

ASD Current Diagnosis, Therapies and their DM Crowley & Associates
Tel 03 9592 7054 e-mail [email protected] Index Page
Table Index
Introduction 7 Objectives 7 Methodology 7 Survey Development Results 9 Conclusions and Recommendations Table Title
Child’s behaviour before diagnosis and after therapy Less common child behaviours before and after therapy Most commonly reported characteristics in Asperger Syndrome “Other” non-biomedical therapies being used Source of influence for use of non-biomedical therapies “Other” sources of influence – non-biomedical therapy use Sources of influence on parents using only non-biomedical Length of time using non-biomedical therapies Helpfulness or effectiveness of non-biomedical therapies Comparative helpfulness/effectiveness non-biomedical Speed of behavioural improvement of non-biomedical therapies Comparative speed of effectiveness of non-biomedical therapies 24 Behavioural improvement within one month non-biomedical Percentages of parents using only non-biomedical therapy or a combination of non- and biomedical therapies Source of influence for use of biomedical therapies Comparison of sources of influence on parents using non- biomedical, both therapy types, or biomedical alone Length of time receiving biomedical treatment Dietary therapies and their effectiveness Comparison of diet effectiveness vs no apparent effect Comparative speed of improvement in behaviour using speech and occupational therapy, with and without biomedical therapy Apparent effectiveness vs non-effectiveness after one month Comparison dietary results with ARI Parent Ratings Survey Speed of behavioural improvement with supplements Comparison of effectiveness of supplements over time Comparison supplement effects with ARI Parent Ratings Survey 39 Speed of behavioural improvements with pharmaceuticals Report on an Internet Based Parent Survey –
Current ASD Diagnosis, Therapies and their Perceived Effectiveness

Dennis M Crowley
This study examines the reasons for the delay between a parent’s first
suspicions of autism and actually obtaining a diagnosis. It presents the main
therapies being used by parents and their perceived effectiveness. The data
were collected through an internet based survey. Of the 331 reponses
received 261 (79%) were completed to varying degrees, of which
approximately 215-235 were able to be used in the analysis. The results
indicate a considerable degree of complacency and/or poor training in relation
to autism among health professionals. Non-biomedical and biomedical
therapies are examined for their perceived effectiveness. Speech and
occupational therapies tend to work on a longer time scale than diet based
therapies, which are found to provide rapid improvements in behaviour in 25-
40% of the cases.
Recommendations are made with regard to the need for better training of
health professionals, and the need to produce a series of biochemical based
screening tests for detecting autism to replace the current tests which are
psychological symptom and time dependant.
Keywords Autism, delayed diagnosis, therapies, diet, training.

Executive Summary
As far as the author is aware, there has never been an investigation into the
delays in diagnosis of autism and the most frequently used therapies in either
Australia or New Zealand. This report is based on the results of an internet
based Parent Survey, aimed at obtaining a snap shot of autism diagnosis,
therapy and perceived effectiveness. Owing to the fact that this is a private,
independent project, and the difficulties in obtaining the cooperation of certain
state based and national organisations, as well as the limitations in providing
information placed on educational institutions, the survey responses were
gathered mainly through informal networks. They are biased towards those
parents who use biomedical therapies or interventions, as opposed to non-
biomedical therapies in the approximate ratio of 4:1.
Despite the very limited number of responses to date, there are a number of
conclusions that can be drawn, as follows:
1. The average delay between a parent’s first suspicion of something being wrong with their child and actually obtaining a diagnosis is approximately 2 years. The main reason for this is GP, paediatric and health professional complacent reassurances that there is nothing wrong with their child and that “the delay is normal and nothing to worry about”. Such comments accounted for just under 50% of the delays. 2. This in turn is due, at least in part, to the lack of adequate autism specific training in universities and other educational institutions. With the incidence of autism currently running between 1:100 and 1:160, there is an urgent need for GPs and other health professionals to be given autism specific training in its diagnosis and the range of therapies available. 3. Nearly 20% of parents were told their child was too young for assessment, and a further ~20% of the delays were due to not being able to get to see a psychologist for a diagnosis earlier. 4. The present delays are also in part due to the fact that to date, diagnosis is dependent primarily on psychological evaluation of the associated symptoms eg lack of speech, poor social and communicative skills, and these tend not to become apparent until the child reaches approximately two years of age (or later in the case of Asperger syndrome). These delays in obtaining a diagnosis are unacceptable and undermine the Early Intervention strategy being promoted by the Federal Government in Australia and the New Zealand Spectrum Disorder Guideline. 5. The most frequently used non-biomedical therapies were found to be speech and occupational (75.3% and 63.0%, n=219). ABA (Applied Behavioural Analysis) was also used by 34.7%. In this survey approximately 80% of parent had used, or were using, biomedical interventions such as dietary modification and supplements in addition to these other therapies. Those parents who were most influenced in choice of therapy by their GP or paediatrician used an average of 2.4 therapies (with a median of 2), whereas those parents most influenced by the internet, or a book they had read, used an average of 4.4 therapies (with a median of 3) on their children. None of the therapies listed in the Survey provided improvement in all children, indicating the great diversity of each child’s individuality. 6. Approximately 50-60% of children on one of the commonly used diets (eg GF/CF=Gluten/Casein Free, GF/CF/SF=Gluten/Casein/Soy free, sugar removed, chocolate remove, salicylate free, SCD =Specific Carbohydrate Diet), showed a behavioural improvement within one month of starting. On the other hand around 20% showed no improvement after one month on diet. 7. Dietary therapies were found to bring about a more rapid improvement in behaviour within a month, than Speech and Occupational Therapy, ABA and Sensory Integration. There appears to be some slight advantage to using a combination of biomedical and speech therapy in order to speed up the rate of speech progress, though the precise nature of the biomedical therapy needs to be examined further. 8. The snapshot did not achieve its objective in terms of obtaining a broad overview of the Australian and New Zealand therapy situation in view of the very small number of participants using only non-biomedical therapies. However those parents who are using biomedical therapies now have access to a reasonable yardstick as to the apparent effectiveness of the various diets and supplements being used by their community. Recommendations arising from the conclusions concern the need for 1. substantial increased funding for education directed at the medical profession and allied health professionals, as well as parents and prospective parents, educators and the children (and adults) affected by ASD. This education needs to incorporate both the latest biochemical and psychological research into autism. 2. substantial increase in government and private funding to help establish research into the underlying biochemical causes of autism. At the present time, there is no one biochemical screening test which clearly identifies autism in the same way that a heel prick or Guthrie test will identify PKU. This report proposes the need to develop an array of tests which will at least identify any biochemical abnormalities in neonatal children, which in turn will enable early biomedical and other interventions, whether a child has autism, Crohn’s, coeliac, or some other genetic, or environmentally induced condition. Such tests would help reduce the uncertainty associated with psychological testing and enable Early Intervention to be “Early”. In depth biochemical screening of those children of parents who suspect something is not quite right with their child, would be a step in the right direction.
The Author

Dennis Crowley is an honours graduate in chemistry (Leeds University, 1966)
and worked in laboratories, sales and marketing, and general management in
the chemical industry in England, France, and Australia for nearly 40 years.
He was CEO of ACNEM (The Australasian College of Nutritional and
Environmental Medicine) in 2007 for a year before retiring (again) to devote
more time to helping the autism community. He first became acquainted with
autism in 2005 through a family connection, and has since become an active
member of the Biomedical Autism Group. He was elected to the board of
Autism Victoria in November 2008.
Vested Interest

Whereas the author admits to being in favour of biomedical therapy, among
others, he has not sought, nor received funding from any company, and has
not carried out the research on behalf of any company or organisation. His
prime interest is to help bring relief to the families of ASD children.

Autism is a condition affecting approximately 1 in 160 children and this rate
appears to be increasing in countries where detailed surveys of its incidence
have been carried out1 2 3.
This survey, aimed primarily at the Australian and New Zealand ASD
community, was prompted by a number of factors as follows:
1. many parent stories to the effect that their GP, or other health professional with whom they were in contact, suggested that there was nothing wrong with their child, and that boys were late developers, compared to girls. 2. a perceived insistence by psychologists that ABA (Applied Behavioural Analysis) was the only proven method to treat autism. 3. the apparent denial by most professional psychologists involved in treating autism that dietary regulation could be a useful tool in helping autistic children’s behaviour. 4. the numerous anecdotes about the dramatic improvements obtained with some children following the application of dietary restrictions, primarily gluten and casein free (GF/CF) diet 5. the Autism Research Institute (ARI) Survey on Parent Ratings of Behavioural Effects of Biomedical Interventions4
As far as the author is aware, there have not been any surveys previously
conducted within Australia and New Zealand to test any of the
abovementioned factors 1-4 statistically. One internet survey in the USA
conducted by The University of Texas at Austin in 20045 captured 552 usable
responses in a 3 month period. This showed that speech therapy was the
most commonly reported intervention (by 70%), followed by visual schedules,
sensory integration and ABA (36%). 52% of parents were using at least one
medication to treat their child, 27% were implementing special diets and 43%
were using vitamin supplements.

A key objective of the survey was to obtain a snapshot of the different types of
treatments being used in Australia and New Zealand with a view to obtaining
parent perspectives on their effectiveness.
Other objectives included:
1. An indication of the delay between the parents first suspicions of autism and diagnosis, and the reasons for the delay. 2. An indication of the effectiveness or otherwise of biomedical treatment. Methodology
Using the internet as a contact medium is a cheap and easy means of
obtaining information. According to the ABS (Australian Bureau of Statistics)
in 2006/7 64% of Australian Households had home internet access and 73%
had access to a home computer. It was considered that similar percentages
would pertain in New Zealand. Thus it was anticipated that an internet based
survey should provide data from a good cross section of the population in
each country.
Survey Development

The survey was based on offering multiple choice questions. The survey
software used was Polldaddy and a specific URL was obtained as shown:
There are 24 questions covering demographic data, delays in diagnosis and
their reasons, who provided the diagnosis, and the therapies used. In order to
encourage participation, none of the questions were made mandatory. One
consequence of this policy was that a number of people clearly visited the
URL just out of curiosity, while others answered some of the questions and
not others.
Most questions had the opportunity to respond with “Other” answers where
the reporter offered alternative options to those provided. Questions also
covered the estimated costs,# and, in the case of biomedical treatment, the
types of tests used. (#This information is not included in this paper).
The survey questionnaire was reviewed by two general practitioners and a
professional statistician, and pilot tested with about 6 parents from the
Melbourne branch of Biomedical Autism Group prior to launch.
Survey Distribution

It was expected that with the help of the state autism organisations, it would
be easy to access the many thousands of families affected by ASD in both
Australia and New Zealand. Regrettably, not all state based organisations in
Australia were prepared to cooperate, and there was very limited response
from the autism organisations in New Zealand. An autism specific school was
also approached in Victoria, but the need to meet privacy and ethics
requirements in dealing with it and any similar schools were overwhelming,
and it became clear the project would not be able to proceed within the
scheduled timeframe. Consequently the response to the survey has been
smaller than anticipated, and very dependent on the good will of various
parent support groups, internet forums, and those individuals who could see
the value in such an exercise. A further consequence is that to date the
responses have been predominantly from parents using biomedical therapy
(plus other therapies) in the ratio of approximately 4:1 compared to those not
using biomedical therapy. This is a much higher ratio than anticipated, given
the anti-biomedical stance taken by many psychologists, health professionals
and teachers. The literature suggests ratios in the order of 3:1 to 1:1 are
probably more representative.6 7 8 It is hoped that as the Survey is ongoing,
many more parents using only non-biomedical therapies will eventually agree
to participate.

The results presented in this paper are based on those responses collected
during the five month period from its launch at the Autism Victoria Research
Forum 6 November 2008, to 6 April. By that time 331 responses were
received, of which 79% were complete (n=261). 61% of the completed
responses indicated they were from Australia, 20% did not provide any
country address, 6% were from New Zealand. There were also 8 replies from
Canada, Hong Kong, UK, and USA.
As expected, Victoria and NSW provided the most replies (95 and 57
respectively). Regrettably, there was minimal input from ACT, NT, Tasmania,
WA families.
Child’s Gender

82% were male and 18% were female, which figures are very broadly in line
with previously published ratios of about 4:1.9 10 11
Child’s first diagnosis
Parents were asked to indicate their child’s first diagnosis and who provided it.
The results are shown in Tables 1, 2, and 3

Table 1

Child’s first diagnosis

First Diagnosis
# ADHD and Epilepsy are not included in DSMIV Section 299 covering Autism. Some parents cited more than one diagnosis. Of the “Other’ diagnoses, the main ones fitted into the following categories: • 10 (4.3%) Global Development Delay (GDD) or developmental delay • 3 expressive or receptive language delay. Provider of child’s first diagnosis

Practitioner N=231
Paediatrician 100
Main “Other” providers of diagnosis

Who diagnosed

Thus the team approach ranks third behind the paediatrician and
psychologist, these three accounting for 86.6% of all diagnoses. If the GP
related diagnoses are added to this percentage then the data suggests that
around 10% of all diagnoses are being made through other channels.
Delays in diagnosis

All childrens’ dates of birth were given, and the median date was 2003, giving
a median age of 5-6 years. (The oldest reported date of birth was 1983). In a
number of cases, some of the reported dates of first suspecting the child was
not developing typically, and the date of diagnosis were given only by the
year, and not month/year. This may indicate the noted delays could be out by
up to twentyfour months in some cases, and only one month in other cases. In
order to minimise such potential discrepancies, the mid year was taken as the
reference point for counting the number of months delay. Thus the average
delay would be expected to be a reasonably representative indicator of the
The average delay from all responses was found to be ~24.4 months (n=228),
though with a very wide range (0-~132 months), and a median delay of ~17
months. Taking PDDNOS, Aspergers and ADHD# as three separate
conditions, the overall result can be broken down as shown in Table 4:
Table 4
Average and median delays in diagnosis

Set/Subset Ave
age Ave age
suspicion diagnosis

^ (1 male with delay of ~120 months excluded)
# Strictly speaking, ADHD is not classified as being on the Spectrum
according to DSM IV (Diagnostic and Statistical Manual of Mental Disorders of
the American Psychiatric Association). However, it was included in the Survey
as some autistic children exhibit ADHD symptoms.
## All male (1 female excluded)
Some parents reported multiple conditions eg Autism, ADHD, or Asperger,
ADHD, in which case Autism or Asperger was taken as the prime condition.
With regard to the responses from parents of Asperger children, the average
age of suspicion for males was 45 months while that for females was only 28
months. It is suspected that this may be due to a mother being able to sense
there is something wrong quicker with a child of her own sex than with a boy.
However, this hypothesis would require a much larger sample number to
determine whether this is in fact correct. The delay in diagnosis is more than
twice that for autism as a whole and nearly x3 that for PDDNOS.
Some other parents gave no diagnosis, which was either an oversight, or that
they had not yet obtained one, or perhaps an indication that they preferred not
to give their child a “label” of autism.
Bearing in mind the slight loss of accuracy in dates mentioned earlier, the
above data regarding average age of suspicion appears to be in line with the
findings that the vast majority of parents notice unusual characteristics in their
ASD children within the first two years of life. De Giacomo and Fombonne12
found that parents began to notice such symptoms at an average age of 19
months, with approximately 30% within the child’s first year. By the time a
child had reached its second birthday, approximately 80% had begun to have
concerns. A similar study in France13 found the average age of recognition
(AOR) was 17 months with 38% of parents being concerned about their
child’s development at 12 months of age and 78% by 24 months.
Parents were asked to indicate which of the following statements best
describe the reason (s) why there was a delay in diagnosis. The results are as
shown in Table 5:
Table 5
Reasons for the delay in diagnosis

Delay Statement
GP advised just normal delay and nothing to worry about Paediatrician advised just normal delay and nothing to worry about Unable to get appointment with psychologist earlier There is some overlap in all the figures as 56 parents cited multiple reasons for the delay, the most significant overlap being that 22 parents cited both their GP and paediatrician indicated it was a “normal delay, and nothing to worry about”. This represents 10.2% of the responses. Overall, the GP or paediatric statements as shown in the table accounted for 40% of the cited delays. It is interesting to note that similar comments from health professionals were made in a survey carried out by La Trobe University researchers in 200214 26.0% indicated there were “Other” reasons for the delay, and the two main features are summarised below: • Reassurances from health professionals, including paediatricians, GPs, MCHNs (Maternal and Child Health Nurses) – 14 (6.5% of total responses) • Reluctance to diagnose, or to accept a label of autism – 6 (2.8% of Thus just under 50% (40%+ 6.5%) of the delays in diagnosis were due to reassurances from health professionals. Given the research findings established in the literature referred to earlier12 13, such results strongly suggest that the medical profession needs to become much more prepared to listen to parents concerns (and act on them in an appropriate manner), rather than just dismiss them as unnecessary worry. The delays in getting to see a psychologist, which accounted for just over 20% of the responses are surprising given that Australia and New Zealand are generally held up as having excellent health systems. Being “too young for assessment” (nearly 20% of the responses), serves to highlight the inadequacy of the present reliance on psychologically based diagnosis. The Australian health system is such that parents need to obtain a referral from a GP before they can see a paediatrician or psychologist. Given the very low diagnosis by GPs (1.7%), it would appear there is an inherent delay built into the system, in obtaining a diagnosis. As they, along with MCHNs, are the first port of call for parents, it would seem appropriate that GPs and MCHNs should be properly trained in being able to recognise and diagnose autism at a very early age in order that parents, and other health professionals, may start applying early intervention. A similar system of referral applies in New Zealand, as well as in the UK. Such delays in the health system tend to be exacerbated in country areas where specialist expertise eg paediatricians and psychologists are in limited numbers, and quite widely dispersed, both in Australia and New Zealand. A recent report by the National Audit Office in the UK15 showed that 80% of GP’s responding to the survey “felt they required additional guidance and training to identify and manage patients with autism more effectively. In particular they mentioned a need for guidance on how to identify possible autism, what referral protocols should be in place, (particularly for adults
suspected of high functioning autism) and what services are or should be
available locally”. The present Survey appears to confirm similar findings in
relation to the Australian, New Zealand situation, i.e. that training in
identification and management appears to be inadequate, even though the
proportion of doctors may not be of the same order.
Child’s behaviour before diagnosis and after intervention

Overall 219 people responded to this multiple choice question relating to 75
behavioural characteristics which may be associated with autism. Parents
were asked what the behaviour of their child was before diagnosis and after
intervention (without specifying which therapies, or how long they had been
employed), with the possibility of current behaviour ranking as “No better” “A
little better”, “Much better”. The following data (Table 6) presents only the
most common characteristics ie those for which >100 responses were
obtained. They are ranked in order of number of observations with the
percentages in the three right hand columns based on the “Before Diagnosis”
Table 6
Child’s behaviour before diagnosis and after therapy

Behaviour Before
No Better
Much Better
to dress himself/herself Does not follow (stimming/rocking) It will be noticed that not all percentages add up to 100% owing to parent input errors. Thus it is clear that therapy does bring about improvement over time in the majority of cases. As can be seen, the highest percentages where there was no improvement are:
Rather surprisingly, the above table does not contain a number of typical
autistic features noted in the literature such as echolalia, speech loss. Table 7
lists those characteristics noted by 50-99 respondents, and it will be observed
that it contains many of these typical autistic traits.
Table 7
Less common child behaviours before and after therapy

Behaviour Before
No Better
Much Better
in switches/ electrical equipment Obsessive speech eg biting From the above table it can be seen that the most intractable characteristics appear to be: • “Bags’ or purple patches under eyes
All the above mentioned improvements are time dependent and it may well be
that many of those parents who registered in the “No better “or “A little better”
columns will eventually see some improvement.
The remaining conditions which attracted less than 50 responses in
descending order were as follows:
Slow eater (48)
Fast eater (47)
Lethargy (47)
High pitched voice (39)
Rashes (37)
Pica (Eating abnormal products eg coal, paint) (34)
Asthma (27)
Rolling eyes (18)
Sick after eating (18)
Urinary tract infections (18)
Seizures (14)
Psoriasis (6)
The most commonly reported characteristics of Asperger children were as
shown in Table 8
Table 8 Most commonly reported characteristics in Aspergers Syndrome

Male (N=27)
Female (N=8)
Total (% of N=35)
It is interesting to note that the ratio of male:female is ~4:1 as for the ASD population as a whole. Also noteworthy is the fact that all female Aspergers were fussy eaters, although this is based on an extremely small sample. Therapies used in the treatment of ASD
For the purposes of this report, these therapies can be split into two

Non-biomedical therapies tend to be those offered by psychologists based on
behavioural research eg ABA as proposed by Ivar Lovaas16 17, or some form
of physical manipulation eg as in cranial osteopathy or sensory/auditory
Biomedical therapies are those which involve dietary intervention,
supplements and/or pharmaceuticals, and chelation (to remove heavy metals
such as mercury and lead or other environmental toxins). The father of the
biomedical approach was Dr Bernard Rimland18 19, a psychologist with an
autistic son. Such therapy is based on the evidence of biochemical
imbalances obtained by testing blood, faeces, urine and hair, as well as
genes. Many ASD children have co-morbidities which researchers are
increasingly suggesting are indicators of the basic cause of autism.20 21 22 23
Both types of therapy have their uses, and in fact most parents using the
biomedical approach also use non-biomedical therapies, especially speech
and occupational therapy. So long as they see progressive improvements in
their child, and their financial situation permits, they will generally continue
with the therapies they believe are effective, and in fact may look around for
more in order to achieve a particular behavioural or health benefit.
Non-Biomedical Therapies Used
Parents were asked to indicate which non-biomedical therapies their child had
received, or were receiving. Non-biomedical therapy was defined as not
involving any special diet, use of supplements or pharmaceuticals. This is
another multiple choice question, with results as shown in Table 9. Details of
“Other” therapies are provided in Table 10.
Note: Except where stated, the data and discussion provided under the
following paragraphs relating to non-biomedical therapies apply to all parents
who responded to the survey, and not just those who use only non-biomedical
Table 9
Non-biomedical therapies being used

Therapy Using/used

“Other” non-biomedical therapies being used

Main “Other” therapies
Using/used (N=219)
Intervention) Miscellaneous applied psychology
# Parents indicated various biomedical and homeopathic interventions in this
section which are covered later in the survey.
NB A few parents indicated they were not using any therapy.
41 parents reported using only non-biomedical therapies, of whom
• 68.3% used Occupational Therapy (OT)
The average number of therapies used per child was 2.4 (median 2) with ST
and OT featuring predominantly.
Source of influence regarding therapy used
Parents were asked “Who or what influenced you to use any of the previously
mentioned non-biomedical therapies?”

215 responses were received, the prime source of influence being the internet
as shown in Table 11:
Table 11
Source of influence for use of non-biomedical therapies

Source of influence

As this was a multiple choice question, many parents indicated several
sources of influence. The lack of grandparent influence is quite remarkable,
and may be attributed to the lack of any knowledge about autism in their days
of child rearing, and also possibly such issues as the dispersed and diverse
nature of families at the present time, compared with say, 30-40 years ago.
Analysis of the “Other” responses is as shown in the following Table 12 (main
replies only)
Table 12
“Other” sources of influence – non-biomedical therapy use

Source of influence
Intervention centres School/kindergarten/teacher 8
In terms of those parents using only non-biomedical therapies (N=41), the
responses were as shown in Table 13 in descending order of importance.
Table 13
Sources of influence on parents using only non-biomedical

Source of influence

# The main “Other” influences were support groups and Early Intervention
programs. Others mentioned were occupational therapist, speech therapist,
teacher, autism community seminars.
Length of time using therapies
Parents were asked how long they had been using non-biomedical therapies.
The results are as shown in Table 14 in descending order of the numbers
using the therapies. There were 211 responses. Figures are given in
percentages except in the final column which is the number who replied.

Table 14

Length of time using non-biomedical therapies

Therapy 0-6

Kinesiology 53.3 13.3 16.7 16.7 0.0 30 Floortime 36.0
The above statistics show a rather unusual pattern in that the speech,
occupational, ABA, and auditory therapy usages for 0-6 months are much
higher than for the 6-12 month period, but then pick up again in the 1-2 year
period. On the other hand, the cranial, kinesiology, N.A.E.T, and neurotherapy
treatments appear to drop off very steeply after 6 months, perhaps being a
measure of their perceived or actual effectiveness (see table 13 below),
and/or their cost. Speech, occupational, ABA, and sensory integration
therapies tend to be used by about 50-60% of the respondents for between1-
5 years with a suspected strong prospect of ongoing therapy after this period.
The length of time spent on a therapy will depend on many factors including
the age of the child, the perceived effectiveness, the cost, whether other
therapies appear on the market, support systems, perceived guilt factors. For
example, ABA has been promoted for many years as the only evidence based
therapy for autism, and therefore presented to parents as being the only
therapy they should be using, even though, along with all the other therapies,
(see Table 15 below#) it does not have a 100% success record. This subject
alone i.e. why parents continue to use some therapies and not others, would
benefit from further study that is beyond the scope of the present paper.
(# RDI® figures, although indicating an apparent exception, are based on a
very limited number of responses).

How helpful/effective have you found non-biomedical treatments to be?

Parents were asked to rate the treatments as one of the following:

The results (in percentages) are as shown in Table 15 where h/e =
helpful/effective (N=213)
Table 15
Helpfulness or effectiveness of non-biomedical therapies
Mildly h/e
stimulation (Tomatis or other) Kinesiology program # Of the 20 parents who gave RDI® as an “Other” therapy, four did not provide an answer to this question and one had indicated a number of (“Other”) therapies, and not just RDI®, so this response was not included. However, based on these extremely limited responses recorded, the figure of 73.3% for “Very Helpful/Effective” and 0% “Not helpful/remarkable,” is noteworthy. The very limited numbers relating to the last four therapies in the list are not
helpful from a statistical point of view.
Therapies may be compared by dividing their helpfulness/effectiveness
(Moderate plus Very) and (Mildly+ Moderately + Very) percentages by the
percentages in the Not Helpful/effective columns, the ratios are as shown in
table 16:

Table 16

Comparative helpfulness/effectiveness non-biomedical

Therapy (Moderate+
(Mild+ Moderate
+ Very)/Not
Osteopathy Kinesiology 1.3 1.8 31 Auditory stimulation (Tomatis or other) Floortime 7.5
Thus it would appear that parents would do well, at least initially, to
concentrate on Speech and Occupational therapies, ABA, Sensory
Integration, and Floortime, although the data for Floortime are very limited.
Speed of Improvement using Non-Biomedical Therapies
Parents were asked how soon the above therapies were effective/helpful with
regard to the child’s behaviour? This question is important as parents will
generally tend to continue using a therapy if they can see an early change in
behaviour. 212 parents replied to this question (N=212)
The options offered were
• No apparent improvement after one month • Some apparent improvement after one month • Immediate improvement (within one week) The data are presented in Table 17 as percentages of the total for each treatment. Table 17 Speed of behavioural improvement of non-
biomedical therapies
Therapy None
Some after
1-4 weeks
stimulation (Tomatis or other) Floortime program The speed of change in behaviour will depend very much on how much therapy is delivered each week, and this question (ie how much therapy/week) was not asked of the parents in order to try to keep the questionnaire as simple as possible. Speech and occupational therapy appear to be effective on a long term basis compared to ABA, but then they are probably not applied with the same intensity as ABA. Comparing Tables 15 and 17, it is important to note the speed of improvement is not the same as the effectiveness or helpfulness. Table 18 compares the apparent effectiveness (by adding the three columns to the left of the total in Table 16) with the apparent lack of effect after one month (the column to the right of the designated therapy). Comparative speed of effectiveness of non-biomedical

Ratio Apparent effect/No
Number (N=212)
apparent effect, after
one month
Neurotherapy 2.5 14 Vision eg Irlen lenses
These ratios need to be viewed with caution, especially where <50 replies
have been received. Of those with >50 replies, ABA stands out as being very
effective. However, this may be due to the intense nature of the treatment
which is normally recommended at a rate of at least 20 hrs/week, and
sometimes up to 40 hrs/week. It is quite possible that many of the other
therapies, particularly speech and occupational therapy would show similar
improvements, if they too were being applied at this tempo. Perhaps the
relevant therapists have been too complacent about the intensity of applying
these therapies in the case of ASD children? Alternatively, if ABA were to be
delivered for only 2-3 hours a week, as is typical of ST and OT, then perhaps
it too would result in a lower ratio than indicated above.
There are insufficient data to draw any firm conclusions about the other
therapies, although it would appear that cranial osteopathy, auditory
stimulation, Floortime, and RDI® may offer noticeable improvements within
one month. Much more data is required.
Another way of looking at these therapies is to examine whether any
behavioural improvement is seen within a month by adding together only the
first two columns to the left of the Total column in Table 17. The results are
shown in Table 19
Table 19
Behavioural improvement within one month non-biomedical

% Improvement within
one month
Neurotherapy 35.7 14 Vision eg Irlen lenses
Again, for those therapies with >50 replies, the stand out therapy is ABA, with
Sensory Integration not far behind, in terms of speed of improvement. Of
those drawing 25 responses or more, all except kinesiology appear to provide
noticeable improvement in about 45-55% of the cases, though the reported
numbers are very low. Kinesiology would appear to be on a par with sensory
integration, though more data are required. As a reminder, these data are
based on responses from all parents, and not just those using only non-
biomedical therapies.

Biomedical Treatment

For the purposes of the survey, parents were advised that biomedical
treatment was to be understood as the intake or avoidance of specifically
designated foods and/or supplements, and/or the removal of toxic metals, as
well as the use of pharmaceuticals.
Before examining the nature of biomedical treatment in detail it is interesting
to compare the parents’ parallel use of non-biomedical therapies.
A total of 148 responses were received indicating a use of one or more non-
biomedical therapy. The average number of biomedical therapies used
(including the biomedical therapy itself) was 4.3 compared with 2.4 for those
parent using only non-biomedical therapies. The median number was 3 cf 2
for the non-biomedical users. Table 20 compares the two populations in terms
of percentages using each therapy:
Table 20
Percentages of parents using only non-biomedical therapy
or a combination of non- and biomedical therapies

Therapy Non-biomedical

Non-biomedical and
biomedical therapies
1. 3 biomedical parents indicated no non-biomedical therapies for their children. It is not known whether this was an oversight, or that they do not think it necessary. 2. 10.1% of parents using biomedical therapy also used RDI®. The figures for speech therapy (82.9% and 76.4%) are broadly in line with the 70% found by Green et al.5 as are those for ABA (36.6% and 35.8%) cf 36.4%. Occupational therapy was not included in the Green survey, so no comparison is possible. However, Green found 38.2% of respondents used sensory integration which is considerably higher than the figures in the present survey. Clearly there is a significant difference between the two parent populations with biomedical parents investing much more in Floortime, Auditory therapy, Kinesiology, Neurotherapy, Cranial Osteopathy, and N.A.E.T., in addition to the biomedical therapy. Factors such as • availability of services eg in the cities c.f. the country areas • acceptance of the health professionals (limited) recommendations (ie • quality of health professionals’ specific autism education
and no doubt many others play a part in the decision making process as to
how parents can do the best to help their children.
Parents were asked who or what influenced them to try a biomedical
approach. The results are as shown in Table 21:
Table 21
Source of influence for use of biomedical therapies

Source of influence
grandparent Article in newspaper/journal
As with the non-biomedical question along the same lines, this was a multiple
choice question so many parents gave more than one answer. With reference
to the “Other” influences there were 6 references to other parents, or parent
support groups, and 4 references to the MINDD# Conferences.
# MINDD Metabolic Immunologic Neurologic Digestive Disorders
Table 22 compares the influences (in percentage terms) impacting in those
parents using only non- biomedical therapies with those who use biomedical
and, though not necessarily, non-biomedical therapies.
Table 22
Comparison of sources of influence on parents using non-
biomedical, both therapies or biomedical alone

Source of influence
Non-biomedical only
Both types of therapies
or biomedical alone
It is disappointing that the survey has reached so few parents using only non-biomedical therapies, which are believed to be in the majority in the community, as this makes statistically valid comparison of the influences difficult. However, as can be seen, there are major differences in influence in
such areas as sourcing information from the internet, reading books,
paediatric and general practitioner advice.

Length of Time Receiving Biomedical Treatment
Parents were asked how long their child had been receiving biomedical
treatment? This question is frequently asked in biomedical parent support
meetings and chatrooms. The simple answer is that each child biomedical
intervention depends on its biochemical makeup and speed of progress. 165
people replied. The results are as shown in Table 23:
Table 23
Length of time receiving biomedical treatment

Years/months Number

The higher percentage for the 0-6 month period may be explained by the fact
that a number of parents try the biomedical approach, and when they do not
see any immediate beneficial effect, they drop the treatment. The data also
show that some parents just try one aspect such as a gluten free diet, or A2
milk and see no benefit. Some diets and supplements just do not result in any
external signs of improvement, though they may well be providing internal
beneficial effects.

Dietary Therapies
Parents were asked what types of diets they had tried or used, and their
effectiveness (in terms of behavioural improvement)? The results are as
shown in Table 24, bearing in mind that many parents try a number of
different diets to find which one best suits their child:

Table 24

Dietary therapies and their effectiveness
effect after effect after
within 1-4
(within 1

# Feingold diet seeks to eliminate all artificial or synthetic colouring,
flavouring, and preservatives, as well as aspartame as an artificial
sweetener.24 It is primarily directed at individuals with ADHD.
It is interesting to note, as with non-biomedical interventions, that in the
population surveyed, none of these diets appear to provide any noticeable
change in behaviour after a month for all ASD children. No one therapy fits all
children’s needs.
The above data may be presented in terms of ratios showing [apparent
effect/no apparent effect] by taking the three columns to the left of the Total
and dividing them by column to the right of the diet, in which no apparent
effect was seen after one month. The results are shown in Table 25 in
descending order of number of responses (except for “Other” – see below):
Table 25
Comparison of diet effectiveness vs no apparent effect

Diet Apparent
apparent effect
diet (SCD) Non-allergenic 7.00 24 GF/CF/SF/low oxalate
The “Other” diets were not specified in the responses received, and so have
no value for the purposes of this exercise.
Speed of change using non-biomedical and biomedical therapies.

There were not enough responses from parents using only non-biomedical
intervention in order to come to any statistical conclusions about the real
speed of change for individual therapies, except perhaps with regard to
speech and occupational therapy. (For instance, there were only 15 people, or
~20% of the total number using ABA, using only non-biomedical therapies,
and of those only 11 gave an indication of speed of improvement). The results
are as shown in Table 26 in percentages (except for Count) where ST =
Speech Therapy and OT= Occupational Therapy:
Table 26
Comparative speed of improvement in behaviour using
speech and occupational therapy, with and without
biomedical therapy

Therapy None
after Some
1-4 weeks
(biomed) The main differences between the two sets of results are that with the biomedical approach, both ST and OT appear to develop more rapidly within the first month - 20.7% vs 13.7% and 26.3% vs 20.8% respectively. Speech improvement is likely to be influenced by which particular biomedical therapy is being used. At the present time Methyl B12 injections are being promoted as an aid to speech by Dr James Neubrander25. 50% of the responses (n=36) (see later under section on supplements) from parents using Methyl B12 indicated a behavioural improvement within one month. A further 19.4% indicated some improvement after one month, while a similar percentage said there was no improvement, and 11.1% said their child got worse, though whether this was in terms of speech or some other behavioural issue, is not known. As nearly all parents apply multiple therapies, especially the biomedical parents, it is not possible to conclude from the broad data in this survey that Methyl B12 is in fact the key factor. As can be seen, speech therapy is usually a long term investment where approximately 80-90% of parents do not see any improvement within one month. The differences in percentages for “None after 1 month” for both ST and OT in
this table may be significant, but more data from the parents using only non-
biomedical therapies is required.
Another way of looking at these results is to compare the apparent
improvement in behaviour (by adding the three columns to the left of Count)
with the “No apparent effect after 1 month” column as shown in Table 27
Table 27
Apparent effectiveness vs non-effectiveness after one

Therapy Ratio
effect/No apparent
effect after 1 month

Comparison with ARI Survey Data

The above answers on the effectiveness in bringing about a change in a
child’s behaviour show considerable differences to the data being collected by
the Autism Research Institute in the USA since 19674 mentioned in the
Introduction. Table 28 compares the two sets of results with behavioural data
in percentage terms. Note the columns titled “No effect” may well be different
as the Australian/NZ data refer to the “No apparent effect after one month” as
shown in Table 24. The ARI survey does not specify a time limit, and is
therefore probably not a valid comparison.
Table 28
Comparison dietary results with ARI Parent Ratings Survey
Better/No N2
worse effect better
free N1 = Numbers of responses in USA N2 = Number of responses in Australia/New Zealand
It is interesting to note that in all cases except Feingold, the ratios for “Got
better/No effect” are higher in Australia and New Zealand than in the USA.
However, the Feingold (and Rotation) diet data for Australia and New Zealand
are extremely low.
The range of ratios N1/N2 for each diet is between 26.7 for GF/CF diet and
81.7 for Feingold diet. The SCD ratio is very low at 9.9 suggesting that it is
perhaps a more popular choice in Australia and New Zealand than Feingold.
Strictly speaking, the ARI survey reports on the basis of “Removed Milk
Products/Dairy, Removed wheat”, which are not necessarily the same as the
strictly gluten/casein free diets as generally understood and practised in
Australia/New Zealand. Similarly “Removed chocolate, removed eggs,
removed sugar” may mean different things to different parents in terms of
whether products may contain these items, or whether it is just preventing the
eating of chocolate, eggs and sugar as separate, clearly identifiable items.
Despite these differences, and given that the ARI survey was one of the
inspirations for the present project, it was thought worthwhile to include some
of the findings in this report.
NB The ARI survey does not provide any information regarding soy free, low
oxalate, non-allergenic, or A2 diets.
Considering these dietary interventions, the gluten, casein, and soy free, SCD
diets, and the sugar removed diet, indicate an approximate 4:1 ratio of
improvement to “no effect”. It would be surprising if such a ratio were
explicable simply in terms of a placebo effect.
Effectiveness of supplements and other biomedical treatments in terms
of significant behavioural improvement, whether in speech or other

Dietary restriction eg to a gluten and casein free diet can lead to a deficiency
in certain nutritional elements such as proteins and minerals. Consequently all
parents using dietary therapies need to provide their children with
supplements in order to compensate for such deficiencies. Many children also
exhibit enzyme deficiencies thought to be due to the presence of heavy
metals, such as mercury and lead, poisoning their biochemical systems, and
leading to downstream anomalies which give rise to abnormal behaviours.
These need to be treated using chelation or other means of encouraging their
removal, eg by using the Pfeiffer protocol26 which involves the use of zinc and
other nutrients, followed by the gradual introduction of metallothionein (MT)
promotion formulations.
A long list (81) of supplements and treatments was offered for parents to
indicate which appeared to benefit the child after 1 week, 1-4 weeks, >1
month. They were also asked to indicate whether their child got worse, or
showed no apparent benefit. Only those responses for which more than 25
replies were received are reported in Table 29 below in descending order of
number of responses. All figures are percentages except for the Total column.
Table 29
Speed of behavioural improvement with supplements

Supplement or
Some Immediate
worse apparent apparent effect
effect> 1 effect >1 within
# “Footsies” are detox foot patches certified as a therapeutic medical device in
Australia (ARTG 151147)
^ Co Q10 is Co-Enzyme Q10
NB Many of the supplements may be provided in a variety of forms eg liquids,
powders, capsules, and the metals in a variety of salts such as zinc sulphate,
or picolinate, selenium methionate or sodium selenate, magnesium citrate or
carbonate etc. For the sake of simplicity the exact chemical entities were not
It is interesting to see that only three products gave a marked improvement
noted by parents within one week, namely Homeopathy (no details requested
or provided), at 42.9%, Melatonin (65.1%) a sleep regulating hormone and
antioxidant, and Olive leaf extract (41%) said to be an antimicrobial and
antioxidant. Note all three apply to <50 cases. On the other hand DMG, a
methylating agent, produced the highest proportion (25%) of children who got
worse out of the 32 cases reported. This is probably due to the child being an
over-methylator. According to Dr William J Walsh27 some 45% of autistic
children are under-methylators and about 15% others are over-methylators.
Overmethylation is generally accompanied by an overabundance of
dopamine, epinephrine and nor-epinephrine, as well as low blood histamine.
Over-methylators require folate and DMAE (dimethyl aminoethanol) among
other supplements in order to help their biochemistry, whereas under-
methylators benefit from DMG, SAMe (S-Adenosyl methionine) among others.
Note there were no adverse effects reported with taurine, a small sulphur
containing amino acid with antioxidant properties. However, like many other
supplements, there are not always any direct external signs that they are
having an effect (good or bad) on the body’s metabolism as can be seen from
the “No apparent effect after one month” column in this table.
Many parents use a number of supplements at the same time, so it is not
always easy to determine which caused what change in behaviour. However,
the results do show quite significant differences, suggesting that in many
cases, they are indeed able to distinguish between products that affect a
child’s behaviour and those that don’t.
The above data may be summarised in ratio format in a similar manner to the
previous tables concerning diets. The following Table 30 illustrates the ratios
(R:1) as indicated:
A Some effect> 1 month + some effect 1-4 weeks + Effect within 1 week
B Some effect within 1-4 weeks + Effect within 1 week
Comparison of effectiveness of supplements over time

Supplement/Treatment A
# As indicated earlier, there were no reports of adverse effects with taurine. Table 30 shows that the products with the highest ratios are as follows:
The remaining products on the list, with the number of responses, are as
shown in Table 31 in alphabetical order.
Table 31
Other supplements or treatments used

Product N

TTFD Thiamine tetrahydrofurfuryl disulphide
Therapies for Asperger Syndrome
The data from the Asperger responses is very limited. However, parents
mentioned biomedical, speech, and occupational therapies as being the most
frequently used or tried (17/35, 15/35 and 13/35 respectively). 14 children
were reported as receiving no non-biomedical therapy, and 8 were reported
as not receiving any therapy at all. Whether this was because the parent
decided not to answer the question, or for some other reason is not known.
• 6/10 (60%) found that a gluten or casein free diet produced some • 13/14 (93%) indicated ST as being very, moderately or mildly helpful. • 8/15 (53%) indicated OT as being very, moderately or mildly helpful.
Very few Asperger children appeared to be receiving supplements. However,
when using fish oil, 3/6 showed some improvement within 1 week and 1/6 got
worse. 3 out of 4 using melatonin showed some improvement within one
week, and 1 got worse.
Comparison with ARI Survey Data

The same observations regarding the ARI Survey as were made earlier apply
equally to the interpretation of the data presented in Table 32 (see p38). The
Australian/ NZ data are taken from Table 29 with decimals rounded up to
whole numbers
As can be seen, there are considerable discrepancies between the Better/No
effect results for each geographic area. This is probably in part due to the fact
that the ARI survey has been collecting data for a number of decades,
whereas the present Parent Survey relates to more recent practices as
indicated by the median age of 5-6 years ie with most children having been
born since 2000. Again the Australian and New Zealand ratios (“Better/No
effect”) are much higher than those observed in the USA.
The range of ratios for N1/N2 for the above supplements is 2.4-181.5 with
Vitamin B6 (2.4), MT Promotor (2.4), Methyl B12 injections (4.7) being at the
lower end and DMG at top of the range. The median ratio is 30.8. Given the
very poor Better/No effect ratio for DMG in the USA at 0.8 (and only 1.2 in
Australia/New Zealand) one wonders why the usage appears to be so high
compared with that in Australia/New Zealand?
The stand out items (Ratio Better/No effect >2.0) in the USA are Detox
(chelation), Methyl B12 (injection), and Melatonin. In Australia/New Zealand,
the stand out items (Ratio Better/No effect >5.0) are Magnesium, Melatonin, Zinc, Enzymes, and Cod liver oil. Comparison supplement effects with ARI Parent Ratings Survey
worse effect better
N1 = Numbers of responses in USA N2 = Number of responses in Australia/New Zealand
Pathology Testing to Assist Biochemical Therapy
Parents were asked to indicate which pathology tests they have used. The
results are as shown below in Table 33 in descending order. 171 people
Table 33
Pathology testing

Test N=171
Hair analysis

# The “Other” tests are as shown in Table 34, of which kryptopyrroles, or
urinary pyrroles, was by far the most frequently mentioned by 10 parents:
Table 34
Other pathology tests used

# KUB = Kidney, ureter, bladder
Pharmaceutical Based Therapies
Very few responses received indicated pharmaceutical use in the treatment of
autism. This is not surprising given that there is no known drug which will
cure, or provide relief, for all autistic symptoms. However, as a number of
pharmaceuticals were mentioned in the abovementioned list of 81
supplements and treatments, the responses are given in the following Table
35 for information only.
Table 35
Speed of behavioural improvements with pharmaceuticals

Product Got
Some Immediate Total
apparent apparent effect
effect >1 effect >1 within
(within 1

Conclusions and Recommendations
The number of people who responded to the Survey during the first 4 months,
was rather disappointing. However it does provide some very broad indication
of the issues facing parents at the present time, and the following initial
conclusions and recommendations to be made. It is anticipated more detailed
studies into the sociological and biochemical aspects of autism will provide
additional support for these findings.
Diagnosis Conclusions
It is clear from the limited data and parent comments (not included in this
paper) that diagnosis is a major concern. The median age of the children in
the Survey was in the order of 5-6 years.
Overall, the GP or paediatric statements to parents accounted for 40% of the cited delays between a parent’s first suspicion of something not being quite right with their child and actually getting an official diagnosis. Just under 50% of the delays in diagnosis were due to reassurances from health professionals (GPs, Paediatricians, MCHNs). Nearly 20% were unable to obtain an immediate appointment with a psychologist and a further ~20% were due to being told the child was too young for assessment. As a result, the average delay for all children surveyed was approximately 2 years, with a median delay of 17 months (N=228), while Asperger children had a diagnosis delay of 38 months, with a median of 36 months (N=32). The delay and median data for ADHD were 43 months and 41 months (N=16), and for PDDNOS, 20 months and 13 respectively (N=13). Whilst the data numbers for Aspergers, ADHD, and PDDNOS are very low, such long average and median delays for these conditions, as well as those for autism, suggest that: 1. there is a degree of complacency towards autism in the medical profession which results in unnecessary delays in diagnosis. 2. there is a lack of proper training in the recognition of autism by the front line health professionals such as GPs and MCHNs. 3. the current psychiatric testing is inadequate in that the criteria are not sufficiently specific to identify many cases of autism and so paediatricians and psychologists tend to advise the parents to “ have another look at him/her in 6 months’ time”. 4. at the present time, psychological testing is considered not possible until a child reaches the age of about 18-24 months, by which time the characteristics which tend to form the basis of testing become more apparent. This results in an inherent delay in obtaining a diagnosis. 5. there is a second inbuilt delay in diagnosis in the health system arising 6. the present diagnostic system is not coping with the numbers of parents trying to get appointments with psychologists. With regard to the principle characteristics of autism, the Survey shows that
the main issues observed by parents (N=219) are

• fine motor delay (tactile problems) 73.5% The main physiological characteristics were
Diagnosis Recommendations
Delays in diagnosis defeat the whole purpose of Early Intervention.
1. The response by GPs and MCHNs to an anxious parent should be to err on the side of caution, rather than to dismiss the parent as having exaggerated fears about their child’s behaviour or development. The New Zealand Guideline is at least a step in the right direction when it recommends “valuing and addressing parental concerns about their child’s development”. The abovementioned characteristics, as observed by parents, particularly the “little or no eye contact”, should be used to help in their diagnosis. 2. There is an urgent need to train GPs and MCHNs, the front line health professionals, in the early recognition of autism, and to be able to give a diagnosis which avoids the need for referral to a paediatrician or psychologist and consequent further delay in obtaining early intervention. Training should include current psychological testing as well as undergraduate education in basic human biochemistry, specifically in relation to autism, but also other similar conditions resulting from genetic and environmental susceptibility. 3. There is an urgent short term need for more psychologists to be trained specifically in autism, including the underlying biomedical aspects. 4. A biochemical screening test, or array of tests, is urgently needed for all neonates to take some of the guesswork out of the psychological
testing and to enable real early intervention to proceed. The USA
Government has recently taken steps to investigate early risk factors
for Autism Spectrum Disorders (ASD). The network, called the Early
Autism Risk Longitudinal Investigation (EARLI), will follow a cohort of
up to 1,200 pregnant women who already have a child with autism28.
The study is considered one of the best-equipped to discover biological
markers and environmental risk factors for autism due to its elevated
autism risk pregnancy cohort, wide ranging data collection with
extensive bio-sampling, length of time it follows pregnant women and
their babies, and multi-disciplinary team of expert investigators. The
EARLI Study is one of eleven National Institutes of Health Autism
Centers of Excellence projects nationwide. Australia and New Zealand
would do well to see whether they would be able to participate, or even
set up a similar project with their Asian neighbours. Every child
diagnosed with autism should at least be investigated for biochemical
imbalances, in order to build up a database which is to be used as a
source of information for research into biochemical treatment.

Therapy Conclusions
41 parents advised they used only non-biomedical therapies, while 148
advised they used biomedical therapies, most of whom also used one or more
non-biomedical therapy. The average number of therapies used by each of the non-biomedically inclined parents was 2.4 with a median number of 2, while the average number used by the biochemically oriented parents was 4.3 with a median of 3. Parents using only non-biomedical therapies are primarily influenced by paediatricians (41.5%) and psychologists (26.8%). Those parents using both biomedical and non-biomedical therapies are more influenced in their choice by the internet (57.6%), reading a book (38.8%) and a friend or family member (30.9%) (N=165). The two key non-biomedical therapies employed by the majority of parents surveyed (N=219) are speech (75.3%) and occupational (63.0%). The next most frequently used therapies are ABA and Sensory Integration used by 34.7% and 28.8% respectively. Very few parents use either no therapy or only one therapy. The percentages of parent using speech, occupational therapy, ABA and sensory integration are broadly in line for those parents using biomedical and non-biomedical approaches. The major differences appear in the biomedical group using much more floortime, auditory therapy, kinesiology, neuropathy, cranial osteopathy and N.A.E.T, as well as the overall biomedical therapy. Factors such as • availability of services eg in the cities c.f. the country areas • acceptance of the health professionals’ (sometimes limited) • quality of health professionals’ specific autism education
are thought to be involved, and this is clearly an area that requires much
further investigation.
ABA appears to be an effective therapy, though whether this is simply due to
the intensity of its application compared to others is no known.
Overall speech and occupational therapies, ABA and sensory integration tend
to produce some beneficial effects in behaviour within a month for
approximately 25-40% of the children. On the other hand approximately 15-
30% show no improvement in behaviour after a month of these therapies. 65-
75% of parents found these four therapies helpful.

The figures for the number of parents using speech therapy (82.9% and
76.4%) are broadly in line with the 70% found by Green et al5., as are those
for ABA (36.6% and 35.8%) cf 36.4% where the first figures in brackets refer
to those using only non-biomedical therapies, and the second figure refers to
those using non-biomedical and biomedical therapies. Occupational therapy
was not included in the Green survey, so no comparison is possible.
However, Green found 38.2% of respondents used sensory integration which
is considerably higher than the figures in the present survey (22.0% and 28.4%). Speech and occupational therapies, ABA, sensory integration, and biomedical therapy are being used for periods up to 5 years in many cases, and beyond 5 years by about 10% of those who responded. Approximately 50-60% of children on one of the commonly used diets (eg GF/CF=Gluten/Casein Free, GF/CF/SF=Gluten/Casein/Soy free, sugar removed, chocolate remove, salicylate free, SCD =Specific Carbohydrate Diet), show a behavioural improvement within one month of starting. On the other hand around 20% show no improvement after one month on the diet. Dietary therapies were found to bring about a more rapid improvement in behaviour within a month, than speech and occupational therapy, ABA, and sensory integration. There appears to be some slight advantage to using a combination of biomedical and speech therapy in order to speed up the rate of speech progress, though the precise nature of the biomedical therapy needs to be examined further. With regard to supplements it is interesting to see that only three products gave a marked improvement noted by parents within one week, namely Homeopathy (no details requested or provided), at 42.9%, melatonin (65.1%) a sleep regulating hormone and antioxidant, and olive leaf extract (41%) said to be an antimicrobial and antioxidant. On the other hand DMG (dimethylglycine), a methylating agent, produced the highest proportion (25%) of children who got worse out of the 32 cases reported. This is possibly related to the child being an over-methylator, and it is preferable that parents find out whether their child has this condition before using such a product. The highest ratios for apparent effectiveness (improvement in behaviour/worse behaviour) of supplements/treatments were found for the following products: The stand out items in terms of the child’s behaviour getting better, compared
with not having any effect, were magnesium (as in Epsom salts), melatonin,
zinc (as in zinc salts), enzymes, and cod liver oil.
Therapy Discussion
With regard to non-biomedical therapies, it would appear that, from a
perspective of helpfulness and effectiveness, parents would do well, at least
initially, to concentrate on speech and occupational therapies, ABA, sensory
integration, and floortime, although the data for floortime are very limited. The
choice from within these therapies will of course depend very much on the
child’s individual needs. Other therapies may be useful where the above
methods are not producing the required results.
With regard to biomedical therapy, this needs to be targeted to each
individual’s particular biochemistry, and this is why substantial pathology
testing may be required in order to expose the underlying disorders. The ten
tests most frequently carried out on the children in descending order were as
follows (N=171):
Generally speaking, it is necessary to carry out more than the standard blood and urine tests. Blood tests expose the presence of mercury and lead over only a short period and not over a longer period as can be obtained using a standard hair analysis. The present standard urine test does not provide any indication of organic acid deficiencies or excess, or the presence of heavy metals. Furthermore, except for the genetic test, many of these tests are usually carried out at regular intervals in order to establish trends in relation to treatment given. Biomedical therapy alone is most unlikely to bring back a child’s speech, which is after all the crucial factor in being able to communicate with the child, but it may well provide the biochemical environment within the brain (and the gut!) such that it is able to pick up speech signals it receives in a cohesive manner, thus facilitating the production of a rational thought and possible answer to a question. Educating the educators is a key issue in making sure that those involved in autism and its treatment are fully aware of the latest research into autism and have an open mind to investigating new ideas. ABA was first proposed by
Lovaas over 20 years ago, and since then there have been a number of
refinements or developments which have led to other therapies such as
Floortime, Son-Rise, RDI®, etc. In a similar manner, the discovery by Dr
Bernard Rimland of the effectiveness of Vitamin B6 and magnesium in the
1960s has led to an enormous amount of research into the biochemistry of
autism, and the development of dietary and other protocols such as GF/CF
diet, Pfeiffer protocol, Methyl B12 injections, HBOT, to produce improved
The insistence by the medical profession that these developments need to be
subjected to double blind placebo cross over trials (The Gold Standard of
proof) has meant that these therapies have received no promotion by the vast
majority of doctors, and in fact have been downplayed by both the medical
profession and the psychologists. However, as can be seen from the results
of this pilot study, many parents do find behavioural improvement in their
children, which is hardly surprising, given that autism has its origins in the
basic genetics and biochemistry of the body, most likely as a result of an
environmental insult. There is a dichotomy in terms of standards of proof
between psychologists’ findings in the treatment of autism that are accepted
just on the basis of using a control group, whereas the general practitioners
require not only a control group, but also a cross over situation, both parts of
which must be run blind, before they will accept that a benefit may exist. It is
practically impossible to run such trials because of ethical considerations. The
products used in the biomedical treatment of autism are for the most part
innocuous eg dietary modification, pre- and pro-biotics, zinc salts etc, except
for the synthetic chelating agents used to extract heavy metals. The benefits
of dietary intervention have been clearly demonstrated in dealing with such
conditions as PKU, coeliac disease, diabetes etc. and the same needs to be
applied in the case of autism. It may well not result in improved behaviour in
all children, but the present study indicates that it should provide benefit in
about 80% of them.
Autism is thought to be a biochemical condition arising from a genetic
susceptibility to an environmental insult. Biochemical research will
undoubtedly bring about advances in the therapeutic treatment of autism in
the same way as it has been used to help people with Syndrome X, coeliac
disease, diabetes, phenylketonuria (PKU), and other metabolic disorders.
Further Research
This Survey has uncovered a number of areas where further research is
required. These include the need
1. to survey GPs, paediatricians, psychologists in the region on how well they feel equipped to correctly identify and manage autism along the lines of the UK survey. 2. to find an agreed array of biochemical/pathology tests which will enable GPs to determine rapidly and with maximum precision those children at risk of autism and other similar conditions. 3. to obtain more input from those parents not using biomedical therapies. 4. to explore the relationship between the medical profession, internet, parental finance, education, and choice of therapies. 5. to explore why parents continue or discontinue therapies 6. to explore exactly how much therapy children do in fact receive 7. to evaluate dietary and other biochemical interventions to determine their effectiveness in controlled trial conditions. 8. to research the annual cost to parents for looking after their ASD children both financially and psychologically. 9. to obtain a more detailed investigation into the speed of effectiveness of therapies in relation to specific suitability for Autism, Aspergers, PDDNOS, CDD and gender, so that cost effectiveness can be determined. 10. to survey universities and other relevant educational institutions to establish the extent of specific training of undergraduate doctors and nurses in autism recognition and management. 11. to investigate the claim by Dr James Neubrander regarding the impact of Methyl B12 injections on speech development.

This Survey is dedicated to all parents with children with autism who kindly
shared their invaluable knowledge and experience in dealing with this most
difficult area of human health. Their fortitude in the face of much adversity is a
credit to them and merits much greater recognition from Government, the
medical profession, the education sector, and the community at large.
Sincere thanks are due to the two GPs and Michael Sichel PhD, who helped
with the medical aspects of the questionnaire, and the statistician who
reviewed its design and results and prefers to remain anonymous.
Many thanks also to the following people and their organisations for their very
generous help in publicising the existence of the Survey: Stephen Penman at
ACNEM (The Australasian College of Nutritional and Environmental
Medicine), in particular the individual ACNEM GPs who kindly offered to
mention the Survey to their ASD clients, Murray Dawson-Smith at Autism
Victoria, Jan Brenton at the Biomedical Autism Group, Judy Nicol at the Bio-
Balance Health Association, Marnie Lo (Walsh Research Institute Sydney
Outreach) and Leslie Embersits of the MINDD Foundation.
Thanks too to AIMA (Australian Integrative Medicine Association), Aspect, the
Australian Centre for Autism Services, Autism Awareness, AFSA, Autism
Spectrum Education Services, AmaGol Services, Cloud 9 Children’s
Foundation (New Zealand), Listen and Learn, MOIRA, Walsh Research
Institute, Webchild and many others, for their help in passing on the word
about the Survey to their members and contacts.
Thanks to Dr David Austin and Kerrie Shandley of SABRI (Swinburne Autism
Biomedical Research Institute) who provided some useful information on
related surveys in the USA in the early stages of developing this project.

Especial thanks to my family, and in particular my wife, for their support
behind the scenes.
Dennis Crowley

1. Chakrabarti S. and Fombonne E. Pervasive development disorders in preschool children: confirmation of high prevalence. Am J Psychiatry 2005 162 (6) 1133-41 2. Autism Advisory Board The prevalence of autism in Australia. Australian Advisory Board on Autism Spectrum Disorders February 2007 3. Baird G. Simonoff E.Pickles A. Chandler S. Loucas T. Meldrum D. Charman T. Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP) Lancet 2006 368 (9531) 210-5 4. Autism Research Institute (ARI) Survey on Parent Ratings of Behavioural Effects of Biomedical Interventions ARI Publ.34/Feb.2008 5. Green V.A. et al. Internet survey of treatments used by parents of children with autism. Research in Developmental Difficulties 2006 (27) 70-842 6. Harrington JW et al. Parental perceptions and use of complementary and alternative medicine practices for children with autism spectrum disorder in private practice. J Dev Behav. Pediatr 2006 27 (2Suppl) S 156-61 7. Wong H H Smith R G Patterns of complementary and alternative medical therapy use in children diagnosed with autism spectrum disorders J Autism Dev Disord 2006 36 (7) 901-9 8. Hanson E et al. Use of Complementary and Alternative Medicine among Children Diagnosed with Autism Spectrum Disorder J Autism Dev Disord 2007 (37) 628-636 9. The Biology of the Autistic Syndromes Gilberg C. Coleman M. (2000 10. 11. Victorian Government Department of Human Services (2003) Report Outcomes – Autism in Victoria: An investigation of prevalence and service delivery for children aged 0-6 years. Melbourne Victoria State Government of Victoria 12. De Giacomo A. Fombonne E Parental recognition of developmental abnormalities in autism Europ Child Adolesc Psych 1998 7 (3) 131-6 13. Baghdadli A et al Relationship between age of recognition of first disturbances and severity in young children with autism Europ Chil Adolesc Psych 2003 12 (3) 122-7 14. Autism in Victoria: An investigation of prevalence and service delivery for children aged 0-6 years. 2002 Department of Education and Early Childhood Development, Victoria. 15. National Audit Office Survey of General Practitioners in England on the subject of Autism 2008 (Incorporated into: Supporting people with autism through adulthood 2009 June 05) 16. Lovaas O.I. Behavioural treatment and normal educational an intellectual functioning in young autistic children J Consult Clin Psychol 1987 (55) 1 3-9 17. Lovaas O.I. et al. Long term outcome for children with autism who received early intensive behavioural treatment Am J Mental Retard.1993 (97) 4 359-372 18. Rimland B. Infantile Autism: the Syndrome and its Implications for a 19. Rimland B. et al. The effects of high doses of Vitamin B6 on autistic children A double-blind cross-over study Am J Psych 1978 135 472-475 20. Pangborn J. An overview of DAN!TM on Autism Causative Factors 21. James S.J. et al Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism Am J Clin Nutr 2004 80 1611-7 22. Shattock P. et al Role of neuropeptides in autism and their relationships with classical neurotransmitters Brain Dysfunction 1990 3 328-345 23. Waring R. et al Biol Psychiatry 1999 1 46 (3) 420-424 24. 25. 26. 27. 28. affer--(final-PDF%20only)/f5679c8c1a17d915d875c50de8e747e4/Symposium%20CJNewschaffer--(final-PDF%20only).pdf

D M Crowley & Associates
74 Dendy St Brighton 3186 Victoria
Tel 0420 830 122 e-mail [email protected] ABN B 1852952X


Five Keys to improving your visibility Being “Findable” means that a business is visible to consumers where and when they’re ready to buy. It also means being found first in their category, before competitors. For local businesses, this used to be fairly simple – run ads in the local newspaper or Yellow Pages, and then rely on customer referrals. But times have changed. Reaching tod


Butrans® patches contain an opioid analgesic PRESCRIBING INFORMATION REPUBLIC OF IRELAND BuTrans ® 5 µg/h, 10 µg/h and 20 µg/h Transdermal Patch Please read the Summary of Product Characteristics before prescribing Presentation: BuTrans 5 µg/h, 10 µg/h, 20 µg/h. Transdermal beige patches effects: anorexia, confusion, depression, insomnia, nervousness, headache,co

Copyright © 2018 Medical Abstracts